M. T. Álvarez-Román, “Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis”, Grhta, vol. 6, no. 1, Oct. 2019.